[P02BB01, trichlorfon, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Metrifonate.]
[J01GA01, streptomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Streptomycin.]
[M03AB01, succinylcholine, Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CA16, sulbenicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Sulbenicillin.]
[N05AL01, sulpiride, Rocuronium may increase the anticholinergic activities of Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06DA01, tacrine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Tacrine.]
[J01CA15, talampicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Talampicillin.]
[N05CD07, temazepam, Temazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC03, terbutaline, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Terbutaline.]
[S01HA03, tetracaine, Tetracaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S03AA02, tetracycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Tetracycline.]
[N05AE05, lurasidone, Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BC07, apomorphine, Apomorphine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L04AX02, thalidomide, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Thiamine.]
[R06AD03, thiethylperazine, Thiethylperazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L01AC01, thiotepa, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Thiotepa.]
[N05CA19, thiopental, Thiopental may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AB08, thioproperazine, Thioproperazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AC02, thioridazine, Thioridazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AF04, thiothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[B02AB01, aprotinin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Aprotinin.]
[N05AL03, tiapride, Tiapride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CA13, ticarcillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Ticarcillin.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Tilidine.]
[P01AB02, tinidazole, The therapeutic efficacy of Rocuronium can be increased when used in combination with Tinidazole.]
[S01AA12, tobramycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Tobramycin.]
[M03BX04, tolperisone, Tolperisone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Rocuronium is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Trazodone.]
[S01BA05, triamcinolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Triamcinolone.]
[N05CD05, triazolam, Triazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03AA06, trichlormethiazide, The serum concentration of Trichlormethiazide can be increased when it is combined with Rocuronium.]
[A03AB12, mepenzolate, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Demecarium.]
[N05AB06, trifluoperazine, Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AD02, trifluperidol, Trifluperidol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AA05, triflupromazine, Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[D07AC02, fluclorolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluclorolone.]
[N04AA01, trihexyphenidyl, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[R03BA07, mometasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Mometasone.]
[A03AA05, trimebutine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AC02, trimethadione, Trimethadione may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Rocuronium is combined with Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AX07, triprolidine, Triprolidine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03BB01, butylscopolamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, Vilazodone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01FA06, tropicamide, The risk or severity of adverse effects can be increased when Rocuronium is combined with Tropicamide.]
[N06AX02, tryptophan, Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03AA02, tubocurarine, Tubocurarine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AA05, tyrothricin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Tyrothricin.]
[A10BH05, linagliptin, The risk or severity of adverse effects can be increased when Linagliptin is combined with Rocuronium.]
[S01AA28, vancomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Vancomycin.]
[N03AX21, ezogabine, Ezogabine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03AC18, indacaterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Indacaterol.]
[C08DA01, verapamil, Verapamil may increase the neuromuscular blocking activities of Rocuronium.]
[N06AX09, viloxazine, Viloxazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N01AX15, xenon, Xenon may increase the neuromuscular blocking activities of Rocuronium.]
[N05AF05, zuclopenthixol, Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J05AE02, indinavir, The risk or severity of adverse effects can be increased when Indinavir is combined with Rocuronium.]
[N03AX14, levetiracetam, Levetiracetam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Ziprasidone.]
[G04BD07, tolterodine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[M03AC04, atracurium, Atracurium may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01FA01, atropine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[H02AB11, prednylidene, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Prednylidene.]
[L04AX01, azathioprine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Azathioprine.]
[J01CA09, azlocillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Azlocillin.]
[M03BX01, baclofen, The therapeutic efficacy of Rocuronium can be increased when used in combination with Baclofen.]
[A08AA11, lorcaserin, Lorcaserin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G04BD12, mirabegron, The risk or severity of urinary retention can be increased when Rocuronium is combined with Mirabegron.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Rocuronium.]
[A02AA05, magnesium silicate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium silicate.]
[C01CA18, octopamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Octopamine.]
[H02AA01, aldosterone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Aldosterone.]
[N05CA04, barbital, Barbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01AA01, acetyldigitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Acetyldigitoxin.]
[J05AE04, nelfinavir, The risk or severity of adverse effects can be increased when Nelfinavir is combined with Rocuronium.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BD02, rasagiline, Rasagiline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA13, lercanidipine, Lercanidipine may increase the neuromuscular blocking activities of Rocuronium.]
[A03FA09, mosapride, Mosapride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06DA02, donepezil, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AC06, thonzylamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C04AX11, bencyclane, Bencyclane may increase the neuromuscular blocking activities of Rocuronium.]
[C03AA01, bendroflumethiazide, The serum concentration of Bendroflumethiazide can be increased when it is combined with Rocuronium.]
[L04AX06, pomalidomide, Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AD07, benperidol, Benperidol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A12CC09, magnesium orotate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium orotate.]
[A06AX06, tegaserod, The therapeutic efficacy of Tegaserod can be decreased when used in combination with Rocuronium.]
[R02AD01, benzocaine, Benzocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A10BX05, pramlintide, The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Rocuronium.]
[N02CC02, naratriptan, Naratriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A12CC05, magnesium aspartate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium aspartate.]
[N04AC01, benztropine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Rocuronium is combined with Levomilnacipran.]
[C08EA02, bepridil, Bepridil may increase the neuromuscular blocking activities of Rocuronium.]
[N06AX26, vortioxetine, Vortioxetine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AG04, vigabatrin, Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA27, droxidopa, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Droxidopa.]
[N05CH03, tasimelteon, Tasimelteon may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A16AA06, betaine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Betaine.]
[S03BA03, betamethasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Betamethasone.]
[C02CC01, bethanidine, The risk or severity of Tachycardia can be increased when Bethanidine is combined with Rocuronium.]
[A03BA03, hyoscyamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03AC19, olodaterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Olodaterol.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Rocuronium is combined with Glycopyrronium.]
[N05CM19, suvorexant, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Dihydrostreptomycin.]
[N05AA04, acepromazine, Acepromazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[V04CX03, methacholine, Rocuronium may decrease effectiveness of Methacholine as a diagnostic agent.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Rocuronium.]
[A06AH03, naloxegol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Naloxegol.]
[N04AA02, biperiden, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Rocuronium.]
[S03AA06, gentamicin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Gentamicin.]
[N06AX11, mirtazapine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Rocuronium.]
[A03AA09, difemerine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Rocuronium is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G02CX02, flibanserin, Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Rocuronium.]
[N05AX15, cariprazine, Cariprazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01EC01, acetazolamide, Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AB07, acetophenazine, Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA05, aprobarbital, Aprobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AX23, brivaracetam, Brivaracetam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA08, bromazepam, Bromazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BC01, bromocriptine, Bromocriptine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A02AD05, aluminum magnesium silicate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium Aluminum Silicate.]
[A03AX08, alverine, Alverine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA19, amineptin, Amineptine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA01, amlodipine, Amlodipine may increase the neuromuscular blocking activities of Rocuronium.]
[N06BX11, aniracetam, Aniracetam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03CA02, bumetanide, Bumetanide may decrease the neuromuscular blocking activities of Rocuronium.]
[N01BB01, bupivacaine, Bupivacaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N07BC01, buprenorphine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, Buspirone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06DA03, rivastigmine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Rivastigmine.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Butorphanol.]
[S01GX07, azelastine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[J01CE04, azidocillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Azidocillin.]
[J01CA06, bacampicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Bacampicillin.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Rocuronium.]
[R03CC12, bambuterol, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Bambuterol.]
[N02BF02, pregabalin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, Beclamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01HA02, benoxinate, Oxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BD03, safinamide, Safinamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Acetylcholine.]
[R03AC17, bitolterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Bitolterol.]
[J05AG03, efavirenz, Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04AA11, bornaprine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[N05AD06, bromperidol, Bromperidol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CD09, brotizolam, Brotizolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03BA02, budesonide, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Budesonide.]
[N05CA03, butobarbital, Butobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA15, butriptyline, Butriptyline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01AA02, acetyldigoxins, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[V04CD06, macimorelin, The therapeutic efficacy of Macimorelin can be decreased when used in combination with Rocuronium.]
[N03AF01, carbamazepine, Carbamazepine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Rocuronium.]
[A03AA03, camylofine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[J01CA03, carbenicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Carbenicillin.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C07AG02, carvedilol, Carvedilol may increase the neuromuscular blocking activities of Rocuronium.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Rocuronium.]
[J01GB14, plazomicin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Plazomicin.]
[N03AX17, stiripentol, Stiripentol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Rocuronium.]
[S01GX12, cetirizine, Cetirizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CM04, carbromal, Carbromal may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AA06, chlorphenoxamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Rocuronium.]
[R03BB08, revefenacin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Rocuronium.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Rocuronium.]
[B01AC23, cilostazol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Cilostazol.]
[A03FA08, cinitapride, Cinitapride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Rocuronium.]
[N06AX29, brexanolone, Brexanolone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA09, clobazam, Clobazam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01AA11, clomocycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Clomocycline.]
[H02AB14, cloprednol, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Cloprednol.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Rocuronium.]
[N05BA22, cloxazolam, Cloxazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[H02AB17, cortivazol, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Cortivazol.]
[J01CF03, methicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Meticillin.]
[N05AA06, cyamemazine, Cyamemazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Rocuronium.]
[N07XX11, pitolisant, The risk or severity of adverse effects can be increased when Pitolisant is combined with Rocuronium.]
[G04BE04, yohimbine, Yohimbine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Rocuronium.]
[H02AB13, deflazacort, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Deflazacort.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Rocuronium.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Dezocine.]
[N05CM21, lemborexant, Lemborexant may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AD10, lumateperone, Lumateperone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02CC07, frovatriptan, Frovatriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A07DA04, difenoxin, Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Dihydrocodeine.]
[N02CC06, eletriptan, Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA16, clevidipine, Clevidipine may increase the neuromuscular blocking activities of Rocuronium.]
[C01BD07, dronedarone, The risk or severity of adverse effects can be increased when Dronedarone is combined with Rocuronium.]
[N03AG02, dipropylacetamide, Valpromide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AA08, dihexyverine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[C01CA14, dopexamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Dopexamine.]
[D07XB03, fluprednidene, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluprednidene.]
[G04BD09, trospium, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, Clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BB02, chlormezanone, Chlormezanone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R02AD04, dyclonine, Dyclonine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA17, levamlodipine, Levamlodipine may increase the neuromuscular blocking activities of Rocuronium.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Rocuronium is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Rocuronium is combined with Oliceridine.]
[P01BA01, chloroquine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Chloroquine.]
[C03AA04, chlorothiazide, The serum concentration of Chlorothiazide can be increased when it is combined with Rocuronium.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AA01, chlorpromazine, Chlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AF03, chlorprothixene, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, The serum concentration of Chlorthalidone can be increased when it is combined with Rocuronium.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BX03, etifoxine, Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Rocuronium is combined with Choline salicylate.]
[N06BX18, vinpocetine, Vinpocetine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BA05, febarbamate, Febarbamate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AX10, felbamate, Felbamate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06BA08, fenozolone, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Fenozolone.]
[R03BA03, flunisolide, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Flunisolide.]
[S02BA08, fluocinolone acetonide, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluocinolone acetonide.]
[R03CC15, formoterol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Formoterol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A02BA01, cimetidine, The risk or severity of adverse effects can be increased when Cimetidine is combined with Rocuronium.]
[N02BF01, gabapentin, Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N07CA02, cinnarizine, Cinnarizine may increase the neuromuscular blocking activities of Rocuronium.]
[L01XA01, cisplatin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Cisplatin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Rocuronium is combined with Citalopram.]
[R06AA04, clemastine, Clemastine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC13, clenbuterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Clenbuterol.]
[J01FF01, clindamycin, The risk or severity of neuromuscular blockade can be increased when Clindamycin is combined with Rocuronium.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Rocuronium.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L01EJ03, pacritinib, The serum concentration of Rocuronium can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AE01, clonazepam, Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Rocuronium.]
[N05AH06, clothiapine, Clothiapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA21, clotiazepam, Clotiazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A04AA01, ondansetron, Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A04AA02, granisetron, Granisetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CF02, cloxacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Cloxacillin.]
[N05AH02, clozapine, Clozapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01GB12, arbekacin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Arbekacin.]
[N05BA13, halazepam, Halazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S02DA02, cocaine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Rocuronium may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Codeine.]
[J01CA18, hetacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Hetacillin.]
[M03AC05, hexafluorenium, Hexafluronium may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB10, hexocyclium, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[S01FA05, homatropine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Homatropine.]
[J01XB01, colistin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Colistin.]
[N01AB07, desflurane, Desflurane may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A04AA03, tropisetron, Tropisetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C04AX28, ifenprodil, Ifenprodil may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03BA08, ciclesonide, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Ciclesonide.]
[R06AX27, desloratadine, Desloratadine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[H01AX01, pegvisomant, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Pegvisomant.]
[C01AA06, lanatoside C, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Lanatoside C.]
[A03AX10, isometheptene, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Isometheptene.]
[N02CC05, almotriptan, Almotriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Rocuronium is combined with Acyclovir.]
[N05BA10, ketazolam, Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Rocuronium is combined with Imatinib.]
[C08CA09, lacidipine, Lacidipine may increase the neuromuscular blocking activities of Rocuronium.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Rocuronium.]
[N03AX09, lamotrigine, Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01GX02, levocabastine, Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01BA03, cortisone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Cortisone.]
[N07BC04, lofexidine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Lofexidine.]
[R06AX13, loratadine, Rocuronium may increase the anticholinergic activities of Loratadine.]
[N05CD06, lormetazepam, Lormetazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium carbonate.]
[B05XA10, magnesium phosphate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium phosphate.]
[C08CA11, manidipine, Manidipine may increase the neuromuscular blocking activities of Rocuronium.]
[A03AA04, mebeverine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, Medifoxamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A08AA09, mefenorex, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Mefenorex.]
[H02AB15, meprednisone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Meprednisone.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Rocuronium.]
[J01CA14, methampicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Metampicillin.]
[N04AA03, methixene, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Cyclandelate may increase the neuromuscular blocking activities of Rocuronium.]
[R03CB02, methoxyphenamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Methoxyphenamine.]
[R06AE03, cyclizine, Cyclizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AD03, metylperon, Melperone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03AA07, cyclopenthiazide, The serum concentration of Cyclopenthiazide can be increased when it is combined with Rocuronium.]
[S01FA04, cyclopentolate, The risk or severity of adverse effects can be increased when Rocuronium is combined with Cyclopentolate.]
[N06AX07, minaprine, Minaprine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01XA18, cyclosporine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02AC05, moxonidine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Cytarabine.]
[M03CA01, dantrolene, The therapeutic efficacy of Rocuronium can be increased when used in combination with Dantrolene.]
[N06BX04, deanol, Deanol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01AA01, demeclocycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Demeclocycline.]
[N05BA16, nordazepam, Nordazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Nefazodone.]
[N05CM16, niaprazine, Niaprazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AG06, tiagabine, Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03AC11, cisatracurium, Cisatracurium may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA05, norfenefrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Norfenefrine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Rocuronium is combined with Escitalopram.]
[G04BD08, solifenacin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[C01AA07, deslanoside, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Deslanoside.]
[D07XC02, desoximetasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Desoximetasone.]
[H02AA03, desoxycorticosterone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Desoxycortone.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S03BA01, dexamethasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Dexamethasone.]
[N06BX07, oxiracetam, Oxiracetam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04AA08, dexetimide, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Rocuronium.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AC01, paramethadione, Paramethadione may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Rocuronium is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Rocuronium.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Rocuronium is combined with Diamorphine.]
[N05BA01, diazepam, Diazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AX07, phenacemide, Phenacemide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CE05, phenethicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Pheneticillin.]
[N03AD02, phensuximide, Phensuximide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA08, dibenzepin, Dibenzepin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S02DA04, dibucaine, Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CF01, dicloxacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Dicloxacillin.]
[A03AA07, dicyclomine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[A03AX04, pinaverium, Pinaverium may increase the neuromuscular blocking activities of Rocuronium.]
[N05AD05, pipamperone, Pipamperone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB14, pipenzolate, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Pirbuterol.]
[C03CA03, piretanide, Piretanide may decrease the neuromuscular blocking activities of Rocuronium.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Diethylcarbamazine.]
[A08AA03, diethylpropion, Diethylpropion may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA03, isradipine, Isradipine may increase the neuromuscular blocking activities of Rocuronium.]
[D07XC04, diflucortolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Difluocortolone.]
[A03AB11, poldine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Digoxin.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Hydromorphone.]
[D04AB07, pramoxine, Pramocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08DB01, diltiazem, Diltiazem may increase the neuromuscular blocking activities of Rocuronium.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BX03, pridinol, Pridinol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AB03, dimethindene, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Procaterol.]
[N03AG05, progabide, Progabide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CE03, propicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Propicillin.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Rocuronium.]
[R06AA02, diphenhydramine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Rocuronium is combined with Diphenoxylate.]
[N05CD10, quazepam, Quazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA23, quinupramine, Quinupramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03FA02, cisapride, Cisapride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AL04, remoxipride, Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC14, reproterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Reproterol.]
[C01BA03, disopyramide, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Distigmine.]
[N07XX02, riluzole, Riluzole may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AX08, risperidone, Risperidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AE09, levocetirizine, Levocetirizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N01BB09, ropivacaine, Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Rocuronium.]
[R03AC12, salmeterol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Dobutamine.]
[A03FA03, domperidone, The therapeutic efficacy of Domperidone can be decreased when used in combination with Rocuronium.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Dopamine.]
[N06AA16, dothiepin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Rocuronium.]
[J01AA02, doxycycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Doxycycline.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Rocuronium is combined with Sertraline.]
[N01AB08, sevoflurane, Sevoflurane may increase the neuromuscular blocking activities of Rocuronium.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Rocuronium.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Rocuronium.]
[N05AL02, sultopride, Sultopride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02CC01, sumatriptan, Sumatriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[V04CX07, edrophonium, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Edrophonium.]
[H01AA01, corticotropin, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Corticotropin.]
[J01CA17, temocillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Temocillin.]
[G04BD05, terodiline, Terodiline may increase the neuromuscular blocking activities of Rocuronium.]
[S01GA02, tetrahydrozoline, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Tetryzoline.]
[M03BX07, tetrazepam, Tetrazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AB05, thiopropazate, Thiopropazate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G04BD01, emepronium, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, Tianeptine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA23, tofisopam, Tofisopam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AG03, toloxatone, Toloxatone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06BA09, atomoxetine, The risk or severity of Tachycardia can be increased when Atomoxetine is combined with Rocuronium.]
[N03AX11, topiramate, The risk or severity of hyperthermia and oligohydrosis can be increased when Rocuronium is combined with Topiramate.]
[C03CA04, torsemide, Torasemide may decrease the neuromuscular blocking activities of Rocuronium.]
[J01AA12, tigecycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Tigecycline.]
[R01AA09, tramazoline, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Tramazoline.]
[N05CD11, triazulenone, Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CM07, triclofos, Triclofos may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB08, tridihexethyl, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[H02CA01, trilostane, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Trilostane.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04AA12, tropatepine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Tulobuterol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Rocuronium.]
[C02CA06, urapidil, Urapidil may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AL06, veralipride, Veralipride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01FB02, ephedrine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Ephedrine.]
[S01GX10, epinastine, Epinastine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX16, venlafaxine, Venlafaxine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CX07, xamoterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Xamoterol.]
[S01GA03, xylometazoline, Xylometazoline may increase the neuromuscular blocking activities of Rocuronium.]
[C08CA12, mepirodipine, Barnidipine may increase the neuromuscular blocking activities of Rocuronium.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Epinephrine.]
[N05CF02, zolpidem, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CF01, zopiclone, Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AX11, zotepine, Zotepine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02AC02, guanfacine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01BG01, moricizine, Moricizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G02AB03, ergonovine, Ergometrine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02CA02, ergotamine, Ergotamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AG01, valproic acid, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CD04, estazolam, Estazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03BA05, fluticasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluticasone.]
[C01CA15, gepefrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Gepefrine.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04AA05, profenamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AB01, ethotoin, Ethotoin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Ethylmorphine.]
[C01CA01, etilefrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Etilefrine.]
[N01AX07, etomidate, Etomidate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AE03, sertindole, Sertindole may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A02BA04, nizatidine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Nizatidine.]
[R06AX12, terfenadine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, Bupropion may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Fluvoxamine.]
[C08CA02, felodipine, Felodipine may increase the neuromuscular blocking activities of Rocuronium.]
[C08EA01, fendiline, Fendiline may increase the neuromuscular blocking activities of Rocuronium.]
[N03AX26, fenfluramine, Fenfluramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Rocuronium is combined with Fentanyl.]
[R03CC02, albuterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Salbutamol.]
[G04BD02, flavoxate, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[J01CF05, floxacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Flucloxacillin.]
[H02AA02, fludrocortisone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fludrocortisone.]
[D07XB01, flumethasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Flumethasone.]
[N07CA03, flunarizine, Flunarizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[D07AC08, fluocinonide, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluocinonide.]
[N06AA14, melitracen, Melitracen may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[H02AB03, fluocortolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluocortolone.]
[V03AZ01, ethanol, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[S01CB05, fluorometholone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluorometholone.]
[N06AB03, fluoxetine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CD01, flurazepam, Flurazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AG01, fluspirilene, Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AA07, framycetin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Framycetin.]
[N06BX17, adrafinil, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Adrafinil.]
[M03AA01, alcuronium, Alcuronium may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G01AX06, furazolidone, Furazolidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03CA01, furosemide, Furosemide may decrease the neuromuscular blocking activities of Rocuronium.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Rocuronium is combined with Eszopiclone.]
[N05AL05, amisulpride, Amisulpride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06DA04, galantamine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Galantamine.]
[M03AC02, gallamine, Gallamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08DA02, gallopamil, Gallopamil may increase the neuromuscular blocking activities of Rocuronium.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Rocuronium is combined with Ganciclovir.]
[N03AA04, barbexaclone, Barbexaclone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX08, bifemelane, Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BC06, cabergoline, Cabergoline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AD03, methsuximide, Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Rocuronium is combined with Alfentanil.]
[H04AA01, glucagon, Rocuronium may increase the gastrointestinal motility reducing activities of Glucagon.]
[N05CM18, dexmedetomidine, Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CE01, glutethimide, Glutethimide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Rocuronium.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Doxazosin is combined with Rocuronium.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Rocuronium.]
[N01AB01, halothane, Halothane may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AH04, quetiapine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, Iprazochrome may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA21, allobarbital, Allobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium citrate.]
[A12CC03, magnesium gluconate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium gluconate.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Rocuronium.]
[N05CA16, hexobarbital, Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC05, hexoprenaline, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Hexoprenaline.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Rocuronium.]
[C08CA10, nilvadipine, Nilvadipine may increase the neuromuscular blocking activities of Rocuronium.]
[M02AA26, nimesulide, Nimesulide may increase the neuromuscular blocking activities of Rocuronium.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Rocuronium can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Hydrocortisone.]
[D07AB02, hydrocortisone butyrate, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The serum concentration of Hydroflumethiazide can be increased when it is combined with Rocuronium.]
[G04BD06, propiverine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[N05AX07, prothipendyl, Prothipendyl may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02AC06, rilmenidine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Rilmenidine.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Rocuronium.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Rocuronium is combined with Sufentanil.]
[N06AA02, imipramine, Imipramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R01AD07, tixocortol, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Tixocortol.]
[M03BX02, tizanidine, Tizanidine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03BA11, indapamide, The serum concentration of Indapamide can be increased when it is combined with Rocuronium.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Rocuronium is combined with Milnacipran.]
[A03AA30, piperidolate, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, Articaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA12, alprazolam, Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CH02, ramelteon, Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AE01, buclizine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Rocuronium.]
[C07AA01, alprenolol, Alprenolol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03BA02, quinethazone, The serum concentration of Quinethazone can be increased when it is combined with Rocuronium.]
[N06AA13, iprindole, Iprindole may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AF05, iproniazid, Iproniazid may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CC06, isoetharine, The risk or severity of Tachycardia can be increased when Isoetharine is combined with Rocuronium.]
[N01AB06, isoflurane, Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01EB07, isoflurophate, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Isoflurophate.]
[N04BX02, entacapone, Entacapone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03CB01, isoproterenol, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Isoprenaline.]
[C04AA01, isoxsuprine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AA24, kanamycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Kanamycin.]
[N01AX03, ketamine, Ketamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02KD01, ketanserin, Ketanserin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J02AB02, ketoconazole, The therapeutic efficacy of Rocuronium can be increased when used in combination with Ketoconazole.]
[N05AH03, olanzapine, Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA22, arbutamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Arbutamine.]
[N04BC09, rotigotine, Rocuronium may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The risk or severity of Tachycardia can be increased when Labetalol is combined with Rocuronium.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Amantadine.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Rocuronium.]
[N07AA30, ambenonium, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Ambenonium.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Rocuronium.]
[N03AX18, lacosamide, Lacosamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Rocuronium can be increased when used in combination with Etacrynic acid.]
[J01CA11, amdinocillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The therapeutic efficacy of Rocuronium can be increased when used in combination with Pivmecillinam.]
[N04BA01, levodopa, The absorption of Levodopa can be decreased when combined with Rocuronium.]
[S02DA01, lidocaine, Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08EX01, lidoflazine, Lidoflazine may increase the neuromuscular blocking activities of Rocuronium.]
[J01FF02, lincomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Lincomycin.]
[N02CA07, lisuride, Lisuride may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA07, lofepramine, Lofepramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A07DA03, loperamide, Loperamide may increase the neuromuscular blocking activities of Rocuronium.]
[N05BA06, lorazepam, Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AH01, loxapine, Loxapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01AA04, lymecycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Lymecycline.]
[B05XA11, magnesium chloride, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium chloride.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium oxide.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium sulfate.]
[N06AA21, maprotiline, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, Mazindol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02BB01, mecamylamine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Mecamylamine.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Mechlorethamine.]
[R06AE05, meclizine, Meclizine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BA03, medazepam, Medazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01AA08, medigoxin, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Metildigoxin.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Rocuronium.]
[P01BC02, mefloquine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, Melatonin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06DX01, memantine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Mephentermine.]
[N03AB04, mephenytoin, Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N01BB03, mepivacaine, Mepivacaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BC01, meprobamate, Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Rocuronium is combined with Meptazinol.]
[N05AC03, mesoridazine, Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AX13, paliperidone, Paliperidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA09, metaraminol, The risk or severity of Tachycardia can be increased when Metaraminol is combined with Rocuronium.]
[A04AA04, dolasetron, Dolasetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01AA05, methacycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Metacycline.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Rocuronium.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03BA09, fluticasone furoate, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Fluticasone furoate.]
[N06BA03, methamphetamine, Metamfetamine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB07, methantheline, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, Methapyrilene may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CM01, methaqualone, Methaqualone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J05AF05, lamivudine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Lamivudine.]
[N03AA30, metharbital, Metharbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G02CB05, metergoline, Metergoline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BA03, methocarbamol, Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA15, methohexital, Methohexital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02BG08, ziconotide, Ziconotide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AA02, methotrimeprazine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The risk or severity of Tachycardia can be increased when Methoxamine is combined with Rocuronium.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03AA08, methyclothiazide, The serum concentration of Methyclothiazide can be increased when it is combined with Rocuronium.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Rocuronium.]
[V04CG05, methylene blue, Methylene blue may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[H02AB04, methylprednisolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Methylprednisolone.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Rocuronium.]
[N05CE02, methyprylon, Methyprylon may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02CA04, methysergide, Methysergide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Rocuronium.]
[C03BA08, metolazone, The serum concentration of Metolazone can be increased when it is combined with Rocuronium.]
[P01AB01, metronidazole, The therapeutic efficacy of Rocuronium can be increased when used in combination with Metronidazole.]
[J01CA10, mezlocillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Mezlocillin.]
[N06AX03, mianserin, Mianserin may increase the anticholinergic activities of Rocuronium.]
[S02AA13, miconazole, The therapeutic efficacy of Rocuronium can be increased when used in combination with Miconazole.]
[N05CD08, midazolam, Midazolam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA17, midodrine, The risk or severity of Tachycardia can be increased when Midodrine is combined with Rocuronium.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Rocuronium.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06BA12, lisdexamfetamine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Lisdexamfetamine.]
[N05AE02, molindone, Molindone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01BD01, amiodarone, Amiodarone may increase the neuromuscular blocking activities of Rocuronium.]
[N06AA09, amitriptyline, Amitriptyline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Morphine.]
[A04AA05, palonosetron, Palonosetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03AC03, vecuronium, Vecuronium may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA02, amobarbital, Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA17, amoxapine, Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AB05, fosphenytoin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Fosphenytoin.]
[J01CA04, amoxicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Amoxicillin.]
[N04BC04, ropinirole, Rocuronium may increase the sedative activities of Ropinirole.]
[J01CF06, nafcillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Nalbuphine.]
[N07BB04, naltrexone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Naltrexone.]
[S01GA01, naphazoline, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Naphazoline.]
[N06BA01, amphetamine, The risk or severity of Tachycardia can be increased when Amphetamine is combined with Rocuronium.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S03AA01, neomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Neomycin.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Rocuronium is combined with Remifentanil.]
[S01EB06, neostigmine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Neostigmine.]
[N05AX14, iloperidone, Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AA19, ampicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Ampicillin.]
[S01AA23, netilmicin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Netilmicin.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Desvenlafaxine.]
[N06AF02, nialamide, Nialamide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA04, nicardipine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Rocuronium.]
[C08CA05, nifedipine, Nifedipine may increase the neuromuscular blocking activities of Rocuronium.]
[C08CA06, nimodipine, Nimodipine may increase the neuromuscular blocking activities of Rocuronium.]
[C08CA07, nisoldipine, Nisoldipine may increase the neuromuscular blocking activities of Rocuronium.]
[N05CD02, nitrazepam, Nitrazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08CA08, nitrendipine, Nitrendipine may increase the neuromuscular blocking activities of Rocuronium.]
[N05CF03, zaleplon, Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BC05, pramipexole, Rocuronium may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AX04, nomifensine, Nomifensine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Norepinephrine.]
[N06AA10, nortriptyline, Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[G02CA02, nylidrin, Nylidrin may increase the neuromuscular blocking activities of Rocuronium.]
[N06AA05, opipramol, Opipramol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Rocuronium is combined with Opium.]
[R03CB03, metaproterenol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Orciprenaline.]
[P01AB03, ornidazole, The therapeutic efficacy of Rocuronium can be increased when used in combination with Ornidazole.]
[C01AC01, ouabain, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Ouabain.]
[J01CF04, oxacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Oxacillin.]
[N05BA04, oxazepam, Oxazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C07AA02, oxprenolol, Oxprenolol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Oxycodone.]
[C01DX03, oxyfedrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Oxyfedrine.]
[S01GA04, oxymetazoline, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Rocuronium is combined with Oxymorphone.]
[N05AE01, oxypertine, Oxypertine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB03, oxyphenonium, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Oxytetracycline.]
[N05AH05, asenapine, Asenapine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03AC01, pancuronium, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Capreomycin.]
[N05CC05, paraldehyde, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[H02AB05, paramethasone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Paramethasone.]
[C02KC01, pargyline, Pargyline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A07AA06, paromomycin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Paromomycin.]
[G04BD11, fesoterodine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, Penbutolol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AG03, penfluridol, Penfluridol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[S01AA14, penicillin G, The therapeutic efficacy of Rocuronium can be increased when used in combination with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The therapeutic efficacy of Rocuronium can be increased when used in combination with Phenoxymethylpenicillin.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Pentazocine.]
[N05CA01, pentobarbital, Pentobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AB10, perazine, Perazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04BC02, pergolide, Pergolide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C08EX02, perhexiline, Perhexiline may increase the neuromuscular blocking activities of Rocuronium.]
[N05AB03, perphenazine, Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Phenazocine.]
[N06AF03, phenelzine, Phenelzine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Rocuronium is combined with Phenformin.]
[N03AA02, phenobarbital, Phenobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Rocuronium.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Rocuronium.]
[A08AA01, phentermine, The risk or severity of Tachycardia can be increased when Phentermine is combined with Rocuronium.]
[S01GA05, phenylephrine, The risk or severity of Tachycardia can be increased when Phenylephrine is combined with Rocuronium.]
[R01BA01, phenylpropanolamine, The risk or severity of Tachycardia can be increased when Phenylpropanolamine is combined with Rocuronium.]
[N03AB02, phenytoin, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Phenytoin.]
[V03AB19, physostigmine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Physostigmine.]
[C08CX01, mibefradil, Mibefradil may increase the neuromuscular blocking activities of Rocuronium.]
[N05AG02, pimozide, Pimozide may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C07AA03, pindolol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01CA12, piperacillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Piperacillin.]
[J05AE01, saquinavir, The risk or severity of adverse effects can be increased when Saquinavir is combined with Rocuronium.]
[N05AC04, pipothiazine, Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A02BX03, pirenzepine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Rocuronium is combined with Piritramide.]
[J01CA02, pivampicillin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Pivampicillin.]
[N02CX01, pizotyline, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, Proxibarbal may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Rocuronium.]
[A03AE01, alosetron, Alosetron may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C03AA05, polythiazide, The serum concentration of Polythiazide can be increased when it is combined with Rocuronium.]
[B05XA01, potassium chloride, The risk or severity of gastrointestinal ulceration can be increased when Rocuronium is combined with Potassium chloride.]
[N05BA11, prazepam, Prazepam may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Prazosin is combined with Rocuronium.]
[S03BA02, prednisolone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Prednisolone.]
[H02AB07, prednisone, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Prednisone.]
[C01DX02, prenylamine, Prenylamine may increase the neuromuscular blocking activities of Rocuronium.]
[N01BB04, prilocaine, Prilocaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N03AA03, primidone, Primidone may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Rocuronium.]
[C01BA02, procainamide, The therapeutic efficacy of Rocuronium can be increased when used in combination with Procainamide.]
[S01HA05, procaine, Procaine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[L01XB01, procarbazine, Procarbazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05AB04, prochlorperazine, Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N04AA04, procyclidine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The risk or severity of adverse effects can be increased when Progesterone is combined with Rocuronium.]
[N05AA03, promazine, Promazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R06AD02, promethazine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[N01AX04, propanidid, Propanidid may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[A03AB05, propantheline, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, Periciazine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CM06, propiomazine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[N01AX10, propofol, Propofol may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Rocuronium is combined with Dextropropoxyphene.]
[C01AB01, proscillaridin, The risk or severity of Cardiac Arrhythmia can be increased when Rocuronium is combined with Proscillaridin.]
[N02CC04, rizatriptan, Rizatriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N06AA11, protriptyline, Protriptyline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R01BA02, pseudoephedrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, Talbutal may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05CA09, vinbarbital, Vinbarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N05BB02, captodiamine, Captodiame may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[M03BA04, styramate, Styramate may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[P02CC01, pyrantel, Pyrantel may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Rocuronium can be decreased when used in combination with Pyridostigmine.]
[R06AC01, pyrilamine, Mepyramine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[C01BA01, quinidine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Quinidine.]
[P01BC01, quinine, The therapeutic efficacy of Rocuronium can be increased when used in combination with Quinine.]
[A02BA02, ranitidine, The risk or severity of adverse effects can be increased when Rocuronium is combined with Ranitidine.]
[C02AA02, reserpine, Reserpine may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[R03AC05, rimiterol, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Rimiterol.]
[G02CA01, ritodrine, The risk or severity of Tachycardia can be increased when Rocuronium is combined with Ritodrine.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01AA09, rolitetracycline, The therapeutic efficacy of Rocuronium can be increased when used in combination with Rolitetracycline.]
[S01FA02, scopolamine, Rocuronium may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[V04CK01, secretin, The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Rocuronium.]
[N04BD01, selegiline, Selegiline may increase the central nervous system depressant (CNS depressant) activities of Rocuronium.]
[J01GB08, sisomicin, The therapeutic efficacy of Rocuronium can be increased when used in combination with Sisomicin.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Rocuronium.]
[C03DA01, spironolactone, Spironolactone may increase the neuromuscular blocking activities of Rocuronium.]
[D07AC14, methylprednisolone aceponate, The risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Methylprednisolone aceponate.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Rocuronium is combined with Ipratropium.]
